Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.
- Conditions
- Advanced Gastric Cancer
- Registration Number
- JPRN-UMIN000015968
- Lead Sponsor
- Tottori University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
1) With history of receiving paclitaxel treatment 2) With peripheral neuropathy greater than Grade2 3) With serious drug allergy 4) With infectious disease and febrile condition (over 38 centigrade) 5) With active double cancers excluding carcinoma in situ and/or prior cancer cured with longer than 5 year interval period 6) With brain metastasis 7) With severe diseases: infectious disease/ uncontrolled DM /poorly controlled hypertension/ myocardial infarction/liver failure/pneumonia or pulmonary fibrosis 8) pregnant or nursing female or male expecting pregnancy of partner 9) Psychological illness 10) Any other patients whom the physician in charge of the study judges to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate (RR)
- Secondary Outcome Measures
Name Time Method Overall survival(OS),Progression free survival(PFS),Time to progression(TTP),Safty